Navigation Links
Trudeau Institute announces a discovery in how FluMist elicits protection
Date:8/23/2011

Saranac Lake, N.Y. New research from the Trudeau Institute may help to explain why live attenuated influenza vaccine (LAIV), commonly known as FluMist, elicits protection. The research is published in this month's issue of Vaccine. The journal article is entitled "Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses" and was authored by Trudeau Institute scientist Dr. Laura Haynes and her colleagues.

"Our research specifically examines how the vaccine, which is commonly known as FluMist, elicits protection," said Dr. Laura Haynes. "Influenza infection normally induces a massive inflammatory response in the lungs that leads to significant illness and increases the susceptibility to secondary bacterial infections. The most efficient way to prevent influenza infection is through vaccination. To date, the mechanism of how FluMist induces protection has been unclear. Our study demonstrates that this vaccine works by inducing a very early non-specific immune response in the lungs in a mouse model of influenza infection."

The very early non-specific immune response sets the stage for the early influx of virus-specific immune cells, which are necessary for viral clearance. Importantly, this immune response is protective against both matching and non-matching influenza strains, therefore it could provide a level of protection in the case of a newly emergent influenza strain.

In addition, this very early immune response also serves to limit lung inflammation by significantly reducing the levels of inflammatory cytokines and chemokines produced following influenza infection. This novel finding provides insight into how this influenza vaccine functions and is important because inflammation is a major cause of damage in the lungs and this can set the stage for secondary bacterial infections, which are quite common following influenza infection.

The study goes on to show that the LAIV vaccine also induces a robust immune response in healthy adult volunteers. These translational experiments were carried out in collaboration with the Respiratory Diseases Research Department at the Naval Health Research Center (NHRC) in San Diego, CA and were the result of a joint Trudeau/Department of Defense contract.

Subjects were recruited by NHRC and were administered the commercially available FluMist vaccine. At specific time points following vaccination, the immune response to the vaccine was examined. Following LAIV vaccination, chemokines and cytokines involved in virus-specific lymphocyte recruitment were produced. This is indicative of a protective immune response and would lead to the early recruitment of immune cells to the lung should influenza infection occur. Importantly, early recruitment of immune cells to the lung is highly desirable since this then leads to accelerated viral clearance and reduced levels of inflammation.


'/>"/>

Contact: Karen Sharma
ksharma@trudeauinstitute.org
518-891-3080
Trudeau Institute
Source:Eurekalert

Related biology technology :

1. Trudeau Institute announces a discovery in the fight against sepsis
2. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
3. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
4. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
5. Cyntellect to Collaborate With the Burnham Institute for Medical Research
6. Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute
7. The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters
8. Stem Cell Profits Five Years Away, Says Repair Stem Cell Institute Chairman to The Wall Street Transcript
9. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
10. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
11. Annual List of Best Doctors in Dallas Showcases Texas Institute for Surgery Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... ... the full spectrum of drug and device development, and Prism Clinical Research ... and clinicians, today announced Verified Clinical Trials (VCT) has been selected ...
(Date:1/19/2017)... Jan. 18, 2017 Acupath Laboratories, Inc., a ... formation of an Executive Committee that will guide the ... John Cucci , a 15-year veteran of ... of Business Development to Chief Sales Officer .  ... served in senior sales leadership roles at several leading ...
(Date:1/18/2017)... According to a new market research report "In situ ... & End User (Molecular Diagnostic Laboratories, Academic and Research Institutions) - Global Forecast ... Million by 2021 from USD 557.1 Million in 2016, growing at a CAGR ... ... MarketsandMarkets Logo ...
(Date:1/18/2017)... , Jan. 18, 2017   Parent Project Muscular ... to end Duchenne muscular dystrophy (Duchenne) , today ... New Jersey Institute of Technology (NJIT) and Talem Technologies ... of robotic technology to assist people living with ... NJIT,s technology – an embedded computer, software, a force ...
Breaking Biology Technology:
(Date:12/20/2016)... 2016   Valencell , the leading innovator ... STMicroelectronics (NYSE: STM), a global semiconductor leader serving ... today the launch of a new, highly accurate ... includes ST,s compact SensorTile turnkey multi-sensor ... sensor system. Together, SensorTile and Benchmark deliver the ...
(Date:12/16/2016)... 2016 Research and Markets has announced the ... Forecast to 2021" report to their offering. ... The biometric vehicle access system ... CAGR of 14.06% from 2016 to 2021. The market is estimated ... reach 854.8 Million by 2021. The growth of the biometric vehicle ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, Inc. ... genomics technology company, announced today that on December 13, ... Department of The Nasdaq Stock Market LLC which acknowledged ... price of WaferGen,s common stock had been at $1.00 ... has regained compliance with Listing Rule 5550(a)(2) of the ...
Breaking Biology News(10 mins):